Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma / 대한내과학회지
Korean Journal of Medicine
; : 224-228, 2014.
Article
de Ko
| WPRIM
| ID: wpr-162308
Bibliothèque responsable:
WPRO
ABSTRACT
Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin's lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Lymphome malin non hodgkinien
/
Lymphocytes B
/
Système nerveux central
/
Liquide cérébrospinal
/
Traitement médicamenteux
/
Neuroimagerie
/
Immunothérapie
/
Lymphomes
/
Méningite
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Korean Journal of Medicine
Année:
2014
Type:
Article